background
rift
valley
fever
rvf
endem
tropic
region
eastern
southern
africa
seropreval
rvf
investig
among
human
popul
borno
state
nigeria
determin
occurr
diseas
studi
area
comparison
lassa
fever
crimeancongo
hemorrhag
fever
method
recombin
nucleoprotein
rnp
base
iggelisa
detect
serum
antibodi
rvf
viru
rvfv
lassa
fever
viru
lasv
crimeancongo
hemorrhag
fever
viru
cchfv
use
test
human
sera
borno
state
nigeria
presenc
neutral
antibodi
rvfvglycoproteinbear
vesicular
stomat
viru
pseudotyp
rvfvpv
also
determin
human
sera
serum
sampl
test
posit
presenc
rvfvigg
serum
sampl
posit
antibodi
lasv
cchfv
respect
posit
correl
titer
neutral
antibodi
obtain
use
rvfvpv
obtain
use
convent
neutral
assay
attenu
strain
conclus
seropreval
rvf
significantli
higher
lasv
cchf
borno
state
nigeria
rvfvpvbase
neutral
assay
develop
studi
potenti
replac
tradit
assay
base
live
virus
diagnosi
seroepidemiolog
studi
rvf
rift
valley
fever
viru
rvfv
zoonot
mosquitoborn
viru
belong
genu
phleboviru
famili
bunyavirida
caus
sever
diseas
human
livestock
throughout
africa
arabian
peninsula
rvfv
also
consid
potenti
bioterror
agent
last
decad
rift
valley
fever
rvf
outbreak
report
eastern
southern
africa
eg
kenya
somalia
unit
republ
tanzania
madagascar
south
africa
contrast
report
recent
occurr
rvf
western
central
africa
signific
highand
lowpreval
cluster
rvf
subnat
area
african
contin
report
sinc
spread
rvfv
larg
depend
mosquito
vector
transloc
anim
host
endem
situat
usual
occur
restrict
geograph
area
inhabit
host
vector
nigeria
rvfv
antibodi
found
sheep
goat
cattl
hors
camel
northern
state
kaduna
sokoto
plateau
area
suggest
viru
may
enzoot
nigeria
addit
serolog
studi
conduct
human
sera
confirm
exist
diseas
nigeria
specif
geograph
locat
borno
state
northeastern
nigeria
share
intern
border
three
african
countri
cameroun
chad
niger
make
vulner
transboundari
spread
variou
diseas
includ
viral
hemorrhag
fever
vhf
addit
borno
state
report
nich
lassa
fever
viru
lasv
possibl
vhf
howev
epidemiolog
rvf
vhf
extens
investig
borno
state
detail
accur
investig
seropreval
necessari
ascertain
occurr
spread
rvf
area
rvfv
possess
singlestrand
tripartit
rna
genom
compos
three
segment
l
segment
encod
nucleocapsid
protein
np
nonstructur
ns
protein
use
ambisens
strategi
segment
encod
precursor
glycoprotein
gn
gc
two
nonstructur
protein
kda
kda
l
segment
encod
l
protein
nucleotid
sequenc
np
gene
highli
conserv
among
variou
rvfv
strain
serum
antibodi
np
readili
detect
earli
infect
convalesc
individu
provid
basi
diagnosi
rvf
tradit
diagnost
assay
vhf
base
immunoassay
use
live
virus
sourc
captur
antigen
use
highli
attenu
rvfv
requir
stringent
biosafeti
measur
could
readili
adopt
laboratori
develop
countri
infrastructur
biosafeti
level
contain
lack
use
recombin
viral
nucleoprotein
rnp
base
serolog
assay
iggelisa
immunofluores
assay
ifa
detect
antibodi
vhf
crimeancongo
hemorrhag
fever
viru
cchfv
lasv
report
recombin
protein
technolog
requir
high
contain
biosafeti
facil
could
readili
meet
demand
simpl
reliabl
system
diagnosi
vhf
also
compar
seroepidemiolog
variou
vhf
cohort
studi
studi
seropreval
rvfv
infect
human
borno
state
nigeria
determin
use
rnpbase
igg
elisa
preval
rvfv
antibodi
compar
hemorrhag
fever
viru
infect
includ
lasv
cchfv
addit
develop
viru
neutral
assay
use
vesicular
stomat
viru
vsv
pseudotyp
virusbear
glycoprotein
rvfv
use
vsv
pseudotyp
system
determin
high
throughput
screen
neutral
antibodi
rvfv
two
hundr
ninetyseven
serum
sampl
collect
septemb
februari
patient
attend
health
facil
govern
hospit
privat
hospit
clinic
local
govern
area
lga
borno
state
northern
nigeria
simpl
random
sampl
techniqu
use
obtain
human
sera
select
lga
consist
least
three
lga
three
senatori
district
north
central
south
also
town
lassa
insect
cell
infect
recombin
baculovirus
express
rnp
rvfv
lasv
cchfv
produc
recombin
histag
rvfvrnp
lasvrnp
cchfvrnp
respect
rnp
purifi
ni
column
chromatographi
qiagen
gmbh
hilden
germani
describ
previous
neg
control
antigen
dp
prepar
baculoviru
acdp
lack
polyhedrin
express
use
protocol
rnp
express
histag
rnp
dp
analyz
sdspage
gel
polyacrylamid
stain
coomassi
blue
biorad
laboratori
hercul
ca
usa
supplementari
figur
iggelisa
perform
describ
previous
briefli
elisa
plate
coat
predetermin
optim
quantiti
purifi
rvfvrnp
lasvrnp
cchfvrnp
approxim
ngwell
overnight
well
plate
cover
ml
pb
contain
skim
milk
tween
sigma
st
loui
mo
usa
pbstm
follow
incub
h
block
plate
wash
three
time
pb
contain
tween
pbst
inocul
test
serum
mlwell
dilut
pbstm
h
incub
period
plate
wash
three
time
pbst
inocul
goat
antihuman
igg
antibodi
label
hrp
dilut
zyme
laboratori
inc
south
san
francisco
ca
usa
h
incub
period
plate
wash
ml
abt
solut
roch
diagnost
mannheim
germani
ad
well
plate
incub
min
room
temperatur
optic
densiti
nm
od
measur
refer
nm
adjust
od
valu
calcul
subtract
od
valu
neg
agcoat
well
correspond
well
mean
plu
three
standard
deviat
elisa
indic
iggelisa
calcul
use
human
serum
sampl
confirm
neg
infect
respect
virus
ifa
data
shown
use
cutoff
valu
iggelisa
order
minim
falseposit
result
could
occur
singl
serum
dilut
igg
respons
consid
posit
sampl
show
adjust
od
valu
cutoff
dilut
convent
neutral
assay
use
infecti
rvfv
strain
perform
describ
previous
briefli
heatinactiv
serum
sampl
dilut
threefold
eagl
minimum
essenti
medium
mem
sigma
st
loui
mo
usa
contain
fb
invitrogen
carlsbad
ca
usa
test
sampl
ml
mix
volum
infecti
dose
plaqu
form
unit
mixtur
incub
h
neutral
incub
mixtur
test
neutral
cytopath
effect
inhibit
assay
use
vero
cell
neutral
antibodi
nab
titer
defin
reciproc
highest
dilut
cytopath
effect
observ
glycoprotein
gp
cdna
clone
vector
construct
rvfvgp
express
plasmid
design
gener
rvfvgpbear
vsv
pseudotyp
rvfvpv
gvsvdgluc
encod
luciferas
gene
kindli
provid
dr
whitt
instead
vsvg
gene
inocul
human
kidney
cell
transfect
transact
royal
societi
tropic
medicin
hygien
h
cultur
supernat
collect
use
work
seed
rvfvpv
dilut
rvfvpv
use
calcul
produc
approxim
rel
light
unit
control
well
serum
sampl
mix
rvfvpv
dilut
mem
sigma
supplement
fb
invitrogen
mixtur
incub
h
neutral
serumrvfvpv
mixtur
transfer
plate
contain
monolay
vero
cell
h
cell
lyse
luciferas
activ
measur
use
brightglo
luciferas
assay
system
promega
madison
wi
usa
accord
protocol
recommend
manufactur
sensit
specif
predict
valu
posit
neg
test
calcul
standard
method
spearman
rank
correl
coeffici
test
roc
curv
twographroc
tgroc
curv
analyz
use
stat
flex
ver
softwar
program
artech
co
ltd
osaka
japan
order
determin
seropreval
rvfv
human
borno
state
nigeria
sera
first
subject
hisrvfvrnpbas
iggelisa
igg
respons
consid
posit
sampl
adjust
od
valu
higher
cutoff
valu
dilut
serum
sampl
analyz
posit
rvfv
igg
tabl
simultan
serum
sampl
also
test
presenc
antibodi
lasv
cchfv
use
rnpbase
igg
elisa
total
sampl
posit
antibodi
lasv
cchfv
respect
tabl
result
indic
high
preval
rate
rvf
studi
area
order
confirm
efficaci
rvfvrnp
antigen
determin
sensit
specif
rvfvrnp
base
elisa
nab
assay
perform
use
human
serum
sampl
examin
posit
nab
antibodi
titer
rang
tabl
thirtyon
sensit
nabposit
sampl
also
posit
iggelisa
specif
nabneg
sampl
also
neg
iggelisa
neutral
assay
vsvbase
rvfv
pseudotyp
viru
neutral
assay
use
vsv
pseudotypebear
glycoprotein
virus
caus
vhf
develop
high
sensit
specif
order
determin
whether
vsvbase
rvfv
pseudotyp
appli
screen
nab
rvfv
infect
produc
rvfvpv
determin
whether
human
sera
collect
studi
area
could
neutral
infect
singl
serum
dilut
assay
rather
titrat
endpoint
dilut
perform
order
establish
highthroughput
screen
nab
sinc
infect
rvfvpv
harbor
luciferas
gene
could
ascertain
determin
luciferas
activ
neutral
activ
sera
repres
percent
neutral
calcul
reduct
luciferas
express
serum
sampl
test
show
luciferas
activ
neutral
remain
show
less
neutral
compar
nonserum
control
tabl
sensit
rvfvpvbase
neutral
assay
determin
compar
result
obtain
convent
neutral
assay
use
serum
sampl
test
posit
neutral
assay
show
neutral
rvfvpv
tabl
furthermor
serum
sampl
less
neutral
none
posit
neutral
assay
tabl
roc
tgroc
analys
perform
order
select
cutoff
point
percent
neutral
use
rvfvpv
figur
cutoff
defin
intersect
point
tabl
summari
result
igg
elisa
serum
neutral
antibodi
nab
assay
use
vsvrvfvpv
nab
assay
use
determin
seropreval
rvfv
human
borno
state
nigeria
sensit
specif
curv
cutoff
valu
neutral
sensit
specif
respect
cutoff
defin
neutral
sensit
would
increas
specif
would
decreas
figur
posit
correl
titer
neutral
antibodi
obtain
use
rvfvpv
obtain
use
convent
neutral
assay
spearman
rank
correl
coeffici
r
calcul
figur
thu
nab
rvfv
screen
rvfvpvbase
neutral
assay
use
singl
serum
dilut
format
studi
seropreval
rvf
investig
among
human
popul
borno
state
nigeria
determin
occurr
spread
diseas
comparison
lassa
fever
cchf
sinc
recombin
proteinbas
immunoassay
high
sensit
specif
demonstr
use
diagnosi
vhf
human
use
rnpbase
iggelisa
detect
serum
antibodi
rvfv
lasv
cchfv
serum
sampl
test
rvfvigg
total
show
posit
result
tabl
antibodi
preval
observ
studi
agreement
result
surveil
studi
carri
sera
collect
locat
throughout
nigeria
found
posit
hemagglutinationinhibit
antibodi
rvfv
studi
signific
differ
preval
antibodi
observ
rvfv
rnpelisa
lasv
rnpelisa
cchfv
rnpelisa
highest
preval
note
rvfv
rnpelisa
antibodi
addit
sampl
test
nab
activ
rvfv
result
indic
rvfv
activ
circul
studi
area
compar
lasv
cchfv
therefor
import
undertak
risk
assess
rvfv
infect
human
nigeria
rvfv
transmit
contact
bodi
fluid
infect
human
anim
mosquito
bite
andor
aerosol
particular
locat
borno
state
share
geograph
border
three
african
countri
indic
region
epidemiolog
studi
conduct
lga
nigeria
also
neighbor
countri
identifi
possibl
risk
factor
transboundari
rvfv
infect
border
porou
unrestrict
human
anim
transact
royal
societi
tropic
medicin
hygien
traffick
across
border
common
throughout
year
spite
activ
circul
rvfv
observ
studi
outbreak
diseas
human
anim
report
studi
area
could
result
poor
surveil
outbreak
diseas
lack
expertis
diseas
recognit
also
possibl
rvfv
circul
region
nonpathogen
strain
rvf
human
usual
begin
nonspecif
influenzalik
acut
fever
progress
seriou
hemorrhag
fever
case
vhf
particularli
lassa
fever
acut
viral
hemorrhag
fever
caus
lasv
report
endem
nigeria
symptom
diseas
also
vari
nonspecif
febril
ill
fatal
viral
hemorrhag
fever
therefor
possibl
patient
nonspecif
febril
ill
caus
rvfv
infect
could
misdiagnos
endem
infecti
diseas
malaria
typhoid
fever
lassa
fever
vsvbase
pseudotyp
system
design
enabl
highthroughput
screen
nab
viral
infect
also
develop
novel
serum
neutral
test
use
rvfvpv
detect
serum
antibodi
rvfv
reliabl
use
assay
evalu
compar
result
assay
obtain
wide
use
goldstandard
neutral
assay
use
infecti
rvfv
serum
sampl
show
neutral
rvfvpvbase
assay
neg
convent
neutral
assay
tabl
possibl
result
neg
sampl
due
falseposit
reaction
vsvrvfvpvbase
assay
howev
among
serum
sampl
one
show
higher
od
valu
cutoff
od
valu
dilut
anoth
one
identifi
posit
rnpbase
elisa
od
valu
dilut
respect
supplementari
tabl
indic
serum
contain
antibodi
rvfv
anoth
possibl
vsvrvfvpvbase
assay
sensit
standard
neutral
assay
use
assumpt
support
observ
nab
titer
measur
use
pseudotyp
vsv
bear
gp
nipah
viru
sarscoronaviru
higher
obtain
use
infecti
virus
roc
tgroc
analys
indic
appropri
cutoff
valu
percent
neutral
demonstr
nab
sera
high
sensit
specif
convent
assay
measur
nab
requir
serialdilut
test
serum
take
sever
day
viru
replic
level
result
plaqueform
cytopath
effect
infect
cell
howev
new
assay
base
rvfvpv
use
singl
serum
dilut
quantit
natur
luciferas
activ
determin
one
day
inocul
onto
cell
final
pseudotyp
vsv
produc
infecti
progeni
virus
therebi
ensur
safe
use
diagnost
tool
taken
togeth
result
indic
rvfvpvbase
assay
measur
nab
safe
rapid
highthroughput
diagnost
capabl
studi
limit
one
rel
small
sampl
size
compar
previou
studi
carri
employ
human
sera
differ
ecolog
zone
nigeria
addit
could
access
detail
inform
subject
age
profess
histori
ill
etc
although
data
obtain
use
recent
serolog
procedur
lack
demograph
inform
studi
subject
make
difficult
provid
advanc
epidemiolog
understand
vhf
nigeria
howev
studi
import
strength
provid
inform
rvfv
infect
high
preval
human
popul
borno
state
demonstr
use
vsvbase
neutral
assay
epidemiolog
investig
result
rnpbase
elisa
shown
approxim
studi
popul
borno
state
nigeria
histori
rvfv
infect
seropreval
rvf
higher
viral
hemorrhag
fever
lassa
fever
cchf
addit
rvfvpvbase
nab
assay
develop
studi
potenti
replac
tradit
assay
base
live
virus
diagnosi
seroepidemiolog
analysi
rvf
endem
nonendem
countri
